Ramacciotti, E., Barile Agati, L., Calderaro, D., Aguiar, V. C. R., Spyropoulos, A. C., de Oliveira, C. C. C., . . . Barbosa Santos, M. V. (2022). Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): An open-label, multicentre, randomised, controlled trial.
Citación estilo ChicagoRamacciotti, Eduardo, et al. Rivaroxaban Versus No Anticoagulation for Post-discharge Thromboprophylaxis After Hospitalisation for COVID-19 (MICHELLE): An Open-label, Multicentre, Randomised, Controlled Trial. 2022.
Cita MLARamacciotti, Eduardo, et al. Rivaroxaban Versus No Anticoagulation for Post-discharge Thromboprophylaxis After Hospitalisation for COVID-19 (MICHELLE): An Open-label, Multicentre, Randomised, Controlled Trial. 2022.